Jaguar Health (JAGX) Income from Continuing Operations (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Income from Continuing Operations of 8723000.0 for Q1 2026, up 182.32% year-over-year from 3089717.8 in Q1 2025, and up 137.61% quarter-over-quarter from 23193000.0 in Q4 2025.
Jaguar Health (JAGX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Income from Continuing Operations for 13 consecutive years, with 8723000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 182.32% year-over-year to 8723000.0; the TTM figure through Mar 2026 stood at 34678000.0 (up 14.33% YoY), while the FY2025 annual figure was 53997000.0, down 37.57% from the prior year.
- Income from Continuing Operations grew to 8723000.0 in Q1 2026 per JAGX's latest filing, from 23193000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8723000.0 in Q1 2026 and bottomed at 23193000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 10283588.24 across 5 years, with a median of 10021000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 126.63% — and 2026, when it soared 182.32%.
- Jaguar Health's Income from Continuing Operations stood at 8232000.0 in 2022, then slipped by 13.08% to 9309000.0 in 2023, then fell by 9.94% to 10234000.0 in 2024, then plunged by 126.63% to 23193000.0 in 2025, then soared by 137.61% to 8723000.0 in 2026.
- Business Quant data shows JAGX's Income from Continuing Operations at 8723000.0 in Q1 2026, 23193000.0 in Q4 2025, and 9648000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 8.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | -23.19 Mn |
| Sep 30, 2025 | -9.65 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -9.63 Mn |
| Mar 31, 2024 | -9.37 Mn |
| Dec 31, 2023 | -9.31 Mn |
| Sep 30, 2023 | -7.90 Mn |
| Jun 30, 2023 | -12.29 Mn |
| Mar 31, 2023 | -12.40 Mn |
| Dec 31, 2022 | -8.23 Mn |
| Sep 30, 2022 | -12.61 Mn |
| Jun 30, 2022 | -9.39 Mn |
| Mar 31, 2022 | -18.16 Mn |
| Dec 31, 2021 | -14.32 Mn |
| Sep 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -14.08 Mn |